SAN FRANCISCO--(BUSINESS WIRE)--Dance Biopharm Holdings, Inc., a privately-held clinical stage biopharma company focused on the development of novel soft mist inhalable formulations of biologics for people living with chronic diseases, today announced presentations of Phase 2 clinical trial results for its inhaled preservative-free human insulin, Dance 501, for the treatment of diabetes. The data will be presented at the 79th Scientific Sessions of the American Diabetes Association (#ADA2019), which will be held June 7-11, 2019 at the Moscone Center in San Francisco.
Details of the poster presentations are as follows:
Title: Dance 501 Inhaled Human Insulin (INH): Linear Dose
Response, Earlier Onset of Action, and Higher Early Effect than s.c.
Insulin Lispro (LIS)
Abstract: Control #2019-A-5548-Diabetes
Poster Board: 1085-P in category 12-E Clinical Therapeutics/New Technology–Insulins
Presenter: Eric Zijlstra, Ph.D.
Session Type: General Poster Session
Session Title: Saturday General Poster Session
Session Date/Time: Saturday June 8, 2019 11:30 a.m. - 12:30 p.m. PT
Location: Poster Hall (Hall F, North, Exhibition Level)
Session Type: ePoster Theater
Session Title: Newest Insulins
Session Date/Time: Sunday June 9, 2019 12:00 p.m. - 1:00 p.m. PT
Location: Exhibit Hall (ePoster Theater B)
About Dance Biopharm
Dance Biopharm is a private company focused on developing novel inhaled formulations of biologics to treat severe and chronic diseases. The company’s novel inhalation delivery technology platform may be utilized with liquid formulations of biologics with the goal of providing effective and convenient treatment options to patients along with wireless connectivity to improve disease management. Dance, headquartered in the San Francisco Bay Area, was founded by John Patton, Ph.D., who has over 25 years of experience developing numerous inhaled therapies. For more information, please visit http://dancebiopharm.com.
All statements other than statements of historical fact included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. We have based these forward-looking statements upon information available to management of Dance as of the date of this release and management's expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to our limited operating history, our ability to successfully develop product candidates, including Dance 501, the cost and uncertainty of obtaining regulatory approvals, our ability to bring product candidates, including Dance 501, to multiple markets and our ability to develop inhaled formulations of other medicines.